What Does the Evidence Say About Ozempic and Gastroparesis?
Latest update (2026-01)
FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Information to Targeted Legal Guidance
If you or someone you know has experienced severe stomach issues like nausea, vomiting, or feeling full quickly after taking Ozempic, you may be dealing with gastroparesis. This condition, where the stomach takes too long to empty, has been increasingly reported in connection with GLP-1 receptor agonists. The long-standing tradition of medical literature and regulatory oversight provides a framework for understanding these risks. This page summarizes published reports and labeling context to help you grasp what the evidence shows and what it doesn't.
Understanding Ozempic and Its Link to Gastroparesis
Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is prescribed to improve glycemic control in adults with type 2 diabetes. However, its use has been associated with a range of gastrointestinal adverse effects, including gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, the pharmacological profile of Ozempic, reported adverse effects, mechanistic pathways linking the drug to gastroparesis, and risk considerations for affected patients, including settlement-related factors. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, and poor glycemic control, complicating diabetes management. While the exact prevalence of Ozempic-induced gastroparesis is not fully characterized, the drug's labeling documents a high incidence of gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Beyond nausea and vomiting, Ozempic is associated with other gastrointestinal adverse reactions occurring at frequencies below 5%, including dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, suggesting that the drug may impair gastric motility.
Mechanistic Pathways and Warning Adequacy
Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying by activating GLP-1 receptors on vagal afferent neurons and enteric neurons, leading to reduced antral contractions and increased pyloric tone. This delay in gastric emptying is a known pharmacological effect, but in some patients, it may become pathological, resulting in symptomatic gastroparesis. The drug's labeling does not explicitly list gastroparesis as an adverse reaction, but the high rates of gastrointestinal symptoms and discontinuation due to these effects indicate a significant risk. The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported in patients treated with the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about gastroparesis, despite the drug's known effect on gastric emptying and the high incidence of gastrointestinal adverse reactions. This gap in labeling may leave patients and healthcare providers unaware of the potential for severe, persistent gastric motility issues. For affected patients, this raises questions about whether the manufacturer provided adequate notice of the risk, which is a key factor in settlement-related considerations.
Settlement Considerations for Michigan Patients
Settlement-related considerations for patients who develop gastroparesis after using Ozempic involve several factors. First, the timeline between exposure to Ozempic and documented harm is important. Gastrointestinal adverse reactions, including those suggestive of gastroparesis, often occur during dose escalation, as noted in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Patients who experience persistent symptoms after starting Ozempic or increasing the dose may have a stronger claim. Second, the severity of harm—such as hospitalization, malnutrition, or need for medical interventions like gastric pacing or feeding tubes—can influence settlement amounts. Third, the adequacy of warnings is central; if the labeling did not sufficiently alert patients to the risk of gastroparesis, the manufacturer may be held liable for failure to warn. Finally, individual patient factors, including pre-existing gastrointestinal conditions and duration of Ozempic use, will be evaluated. In Michigan, patients affected by Ozempic-related gastroparesis may seek legal recourse through product liability lawsuits. The state's laws on failure to warn and defective design apply. Settlement negotiations often consider the strength of medical evidence linking the drug to the condition, the timing of symptoms relative to drug initiation, and the presence of other contributing factors. Given the high rate of gastrointestinal adverse reactions in clinical trials and the lack of a specific gastroparesis warning, affected patients may have a viable claim.
Next Steps for Affected Individuals
In summary, Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug's mechanism of slowing gastric emptying supports a causal link, yet the labeling does not explicitly warn of this risk. Patients in Michigan who develop gastroparesis after using Ozempic should consider consulting a legal professional to evaluate their case, particularly regarding the adequacy of warnings and the timeline of harm. References: (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is gastroparesis and how is it linked to Ozempic?
Gastroparesis is a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms like nausea, vomiting, early satiety, and abdominal pain. Ozempic, a GLP-1 receptor agonist, slows gastric emptying as part of its mechanism, which can become pathological in some patients, resulting in symptomatic gastroparesis. Clinical trials show high rates of gastrointestinal adverse reactions, including nausea and vomiting, which overlap with gastroparesis symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Does Ozempic's labeling warn about gastroparesis?
No, the prescribing information for Ozempic does not explicitly list gastroparesis as an adverse reaction. It includes warnings about serious hypersensitivity reactions but lacks a specific warning about gastroparesis, despite the drug's known effect on gastric emptying and high incidence of gastrointestinal adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap may be relevant in legal claims for failure to warn.
What factors influence an Ozempic gastroparesis settlement in Michigan?
Key factors include the timeline between Ozempic exposure and documented harm (often during dose escalation), severity of harm (e.g., hospitalization, need for medical interventions), adequacy of warnings, and individual patient factors such as pre-existing conditions and duration of use. Michigan product liability laws on failure to warn and defective design apply.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.